THE REVIEW OF CROMOLYN SODIUM by William H. Kelly, Pharm.D., in this issue (page 22) discusses several points that should make this agent the drug of choice for children with chronic mild-to-moderate asthma in the U.S., as it is in the United Kingdom and other countries. This drug has been underused in the U.S. for several reasons, including: initial approval by the Food and Drug Administration for steroid-dependent asthmatics; the rise in popularity of theophylline as numerous studies revealed a safe and effective plasma concentration range and described its pharmacokinetics; the development of sustained-release theophyllines that simplified dosing regimens; the lack of a convenient dosage form that did not require discontinuation during acute attacks; and the high cost of the cromolyn sodium. Some of these barriers, cost in particular, continue to make cromolyn sodium a drug with limited use. However, the risk to benefit ratio of cromolyn sodium, as well as its action on the late asthmatic response, tips the scales in favor of this drug, particularly in children in whom learning and behavior problems associated with theophylline are becoming increasingly apparent.
The clinical benefits of cromolyn sodium may not be apparent for three weeks or more. However, as noted by Kelly, it has been equal to theophylline in clinical response in all studies in which an adequate follow-up period was allowed.
The emerging importance of the late asthmatic response, however, makes the action of cromolyn potentially superior. The late asthmatic response, when patients undergo a second bronchoconstrictive response 4-12 hours after an initial acute bronchoconstriction caused by exposure to an allergen, is thought to be induced by mast cell-derived mediators.' As Kelly mentioned, studies have associated late asthmatic responses with a prolonged increase in nonspecific airway hyperreactivity," more frequent asthma attacks in children," and greater compatibility with symptoms of chronic and severe asthma." At least half of the children with chronic asthma exhibit late asthmatic responses." Theophylline and beta-agonists do not affect late asthmatic responses, but cromolyn does. Consequently, its selection in chronic asthma may prevent the development of more severe asthma as mast cell mediators are released.
Another important consideration is the recent focus on impaired learning and behavioral problems associated with theophylline therapy and the absence of such effects when cromolyn sodium is substituted. Furukawa et al. reported learning and behavioral problems in about five percent of school children receiving theophylline." This led them to carefully study six children, ages 6-13 years, who had been on chronic daily theophylline (1-6 years) and whose parents were concerned about learning and behavioral difficulties. A single-blind study was used to compare theophylline to cromolyn sodium, and parents and psychologists were unaware when cromolyn and a theophylline placebo were used in place of theophylline. Stopping theophylline resulted in improved psychological scores for measures of attention, concentration, and memory, and maternal perceptions of improvement in restlessness, distractibility, irritability, manageability, and sleeping." Springer et al. also noted poorer performances on psychological tests reflecting visual-spatial planning in four children when these children received theophylline, but not during cromolyn therapy. These children had IQ scores of 87 to 105. Nine children with higher IQ scores (111-134) did not have this adverse effect from theophylline, leading the authors to speculate that children with lower intelligence may be most susceptible to this adverse effect. 7 A recent study by Rappaport et al. of 17 children with normal intellience also revealed no adverse effects on learning and behavior. B This may strengthen the observations of Springer et al. 7 It should be noted, however, that the six children studied by Furukawa et al. had IQ scores of 101 to 126,6 so further study of the susceptible group is needed. In addition, as noted by Selcow et aI., parents may not complain of behavioral problems until carefully questioned.? This has also been our clinical experience. In fact, in our county asthma clinic, we believe approximately 10-20 percent of the children develop school or behavior problems attributable to theophylline. As noted by Furukawa et al. these problems occur at therapeutic and even subtherapeutic serum theophylline concentrations." Our clinical observations are consistent with the reports of otherst"!" that similar toxicities are not exhibited when the children are treated with cromolyn sodium, and disappear when children on theophylline are changed to cromolyn sodium. The problems with visual-spatial planning can result in difficulty with sequencing letters for spelling and numbers for mathematics, and ultimately result in school failure. Learning processes in preschool children may also be impaired although this remains to be studied. The behavioral problems can disrupt the entire family. If these complications can be avoided by using an equally effective alternative medication, i.e., cromolyn sodium, this course seems worthwhile.
The routine use of cromolyn sodium must be balanced against the relatively greater cost and more frequent dosing when compared with theophylline. However, even these differences are probably exaggerated since after several months of cromolyn sodium therapy, many patients can have doses reduced to three and occasionally two times daily. In addition, absorption of sustained-release theophyllines may be unreliable in younger children. The cost of theophylline serum concentration measurements must also be added to the cost of theophylline therapy and these can be quite numerous unless a child is extremely well controlled on theophylline. Most clinicians feel compelled to recheck theophylline concentrations during exacerbations of asthma as well as during acute symptoms consistent with theophylline toxicity, such as gastrointestinal complaints and headaches commonly associated with viral illnesses seen in children. This can result in significant expense as well as considerable discomfort and anxiety for the child because of the venipunctures. In light of recent concerns about learning problems, an appropriate additional expense may be psychometric testing before and during theophylline therapy.
Theophylline remains an extremely effective drug for treating chronic as well as intermittent asthma. The contributions of many investigators have helped describe its pharmacokinetics and an optimal therapeutic range, thus promoting its safe and effective use. Despite this, the acute occurrence of many factors altering theophylline clearance (e.g., viral infections) are unpredictable and toxicity is serious and potentially fatal. Theophylline also causes learning and behavioral toxicity in children even at low serum concentrations. Finally, it lacks activity against the late asthmatic response associated with a large percentage of chronic asthmatic problems in children. Cromolyn sodium does exert its effect against late asthmatic response, has almost no toxicity, and does not require repeated venipunctures for monitoring. The cost differences associated with cromolyn do not seem sufficient to justify the risks and discomforts of theophylline as the preferred drug for asthma for children with chronic disease. Patient education on the proper use of cromolyn sodium delivery systems will be a vital role for clinical pharmacists for ultimate therapeutic success with this drug. It is time to seriously consider cromolyn sodium as an equal and probably preferred drug for children with chronic asthma.
